Integrated BioPharma Q1 Swings to $691K Net Loss as Sales Fall 21.9%
INBP sits 20% above its 52-week low of $0.138 on light trading volume (0.1× avg).
Summary
Integrated BioPharma swung to a $691K net loss on a 21.9% sales decline, with gross margin turning negative and $1.2M of cash used in operations. Cash fell to $3.1M, leaving the undrawn PNC revolver as the key liquidity source.
Updates
· Wiseek News — Integrated BioPharma's quarterly revenue fell 22% to $9.9M from $12.7M a year earlier, with top two customers at 88% of revenue versus 87%.
- Operating loss was $1.0M versus $0.2M operating income in the prior-year quarter.
Key Events · Earnings and Guidance · INBP
-
Q1 Sales Drop 21.9%
Net sales fell to $9,913 thousand from $12,689 thousand, driven by a $2,384 thousand decline in purchases by Life Extension within Contract Manufacturing.
-
Gross Margin Turns Negative
Cost of sales of $10,025 thousand exceeded revenue, producing a $112 thousand gross loss versus $1,019 thousand gross profit a year earlier; net loss was $691 thousand versus $123 thousand net income.
-
Operating Cash Burn of $1.2M
Net cash used in operating activities was $1,219 thousand versus $1,301 thousand provided a year earlier, and cash fell to $3,116 thousand from $4,471 thousand at June 30, 2026.
-
PNC Covenant Miss Awaits Waiver
The company did not meet its 1.10 to 1.0 fixed charge coverage ratio at June 30, 2026 and has requested a waiver from PNC; no debt was outstanding under the lines of credit at September 30, 2026.
Analysis · INBP · Life Sciences
The quarter deteriorated sharply: sales fell 21.9% to $9.9M, cost of sales exceeded revenue, and the company posted a $112K gross loss versus a $1.0M gross profit a year ago. The revenue drop is concentrated — Life Extension purchases fell $2.4M — and with two customers still at 88% of consolidated sales, there is little cushion. Cash fell to $3.1M and operations burned $1.2M in the quarter, so the $4.25M undrawn PNC revolver is now the main liquidity backstop; management says operations plus that facility cover requirements through November 13, 2027. The company also disclosed it missed its PNC fixed charge coverage ratio at June 30, 2026 and is awaiting a waiver.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBP was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.14 to $0.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.